Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin-Reference-Cited by-同舟云学术

Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin

Published:2014-10-15 Issue:11 Volume:53 Page:975-988
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Kadokura Takeshi,Zhang Wenhui,Krauwinkel Walter,Leeflang Stefanie,Keirns James,Taniuchi Yuta,Nakajo Ikumi,Smulders Ronald

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-014-0180-z.pdf

Reference45 articles.

1. Shaw J, Sicree R, Zimmet P. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

2. International Diabetes Federation. Global guideline for type 2 diabetes 2005. Section 6: glucose control levels. http://www.idf.org/global-guideline-type-2-diabetes-2005 . Accessed 2 Oct 2013.

3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.

4. Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272–7.

5. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95:34–42.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease;World Journal of Cardiology;2023-07-26

2. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects;Expert Opinion on Drug Metabolism & Toxicology;2023-07-03

3. SGLT2 Inhibitors as Potential Anticancer Agents;Biomedicines;2023-06-30

4. Current analytical methods to monitor type 2 diabetes medication in biological samples;TrAC Trends in Analytical Chemistry;2023-01

5. Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds;Egyptian Journal of Basic and Applied Sciences;2022-11-28